Vedere Bio recently became a wholly-owned subsidiary of Novartis after being acquired by the pharma giant for up to $280 million–$150 million upfront, up to $130 million in milestones—in a deal designed to bolster the buyer’s expanding presence in gene therapy . . .
The post A New Vision for Gene Therapy appeared first on GEN – Genetic Engineering and Biotechnology News.
